GPC5-AS1: GPC5-AS1, a long non-coding RNA (lncRNA), has been implicated in metastatic melanoma and identified as one of the six differentially expressed lncRNAs correlated with reduced survival time in patients with metastatic melanoma [PMC6487673]. Silencing GPC5-AS1 with shRNA in BGC-823 cells resulted in a reduction of GPC5-AS1 expression, which was found to contribute to the tumorigenicity of these cells [PMC8908922]. These findings suggest that GPC5-AS1 may play a role in the progression and prognosis of metastatic melanoma, potentially serving as a prognostic marker. Further research is needed to understand the exact mechanisms by which GPC5-AS1 influences tumor progression and survival outcomes in patients with metastatic melanoma. References: [PMC6487673] Liu, Y., Sun, J., Zhao, M., Ouyang, H., Yang, J., & Zhao, M. (2019). Identification of key lncRNAs correlated with reduced survival time in patients with metastatic melanoma based on RNA-seq data analysis. Cancer management and research, 11, 2019–2032. [PMC8908922] Liu Y., Sun J., Yang J., & Zhao M. (2020). Silencing long non-coding RNA GPC5‑AS1 inhibits tumorigenicity of BGC‑823 cells by downregulating miR‑513a‑3p expression levels. Molecular Medicine Reports, 23(5), 1-10.